Guangzhou Baiyunshan’s Subsidiary GP Corp. to Begin Trading on NEEQ

Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an announcement.

Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Pharmaceuticals Co., Ltd (GP Corp.), will commence public trading on the National Equities Exchange and Quotations (NEEQ) starting 20 May 2025. This move, approved by the Hong Kong Stock Exchange, positions GP Corp. in the innovation tier of NEEQ, potentially enhancing its market visibility and investor engagement.

The most recent analyst rating on (HK:0874) stock is a Hold with a HK$25.40 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.

More about Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. It focuses on the development and distribution of pharmaceutical products and services.

YTD Price Performance: -5.60%

Average Trading Volume: 1,444,254

Technical Sentiment Signal: Sell

Current Market Cap: HK$44.63B

For an in-depth examination of 0874 stock, go to TipRanks’ Stock Analysis page.